

TAYSIDE PRESCRIBER

ADTC Supplement – No 6

Issue 6

September 1999

In this issue:

- **REORGANISATION OF ADTC**
- **NEW DRUGS SUB-GROUP**
Raloxifene (Evista®)
- **APPEALS PROCEDURE**
Details of a mechanism for appealing against decisions by ADTC regarding the introduction of new drugs
- **FORMULARY SUB-GROUP**
Update on the 4th edition of the Tayside Area Drug Formulary
- **NOTIFICATION OF NEW DRUGS**
Zanamivir (Relenza®)

REORGANISATION OF ADTC

A reorganisation of The Area Drug & Therapeutics Committee (ADTC) and its Sub-Groups is taking place in order to reflect the new Trust structures in Tayside. The ADTC is engaging in dialogue with Trusts and has reviewed its role and current membership.

NEW DRUGS SUB-GROUP - RALOXIFENE (Evista)

Category 1. Recommendation for general use

Summary: Raloxifene is recommended for use in women with established post-menopausal osteoporosis who are unable to take HRT (for whatever reason) and likewise unable to take bisphosphonates.

The above is based on level Ib evidence (i.e. results from at least one randomised controlled trial).

APPEALS PROCEDURE

The ADTC categorises drugs according to the classifications listed overleaf (see proforma). Individual clinicians who disagree with the classification ascribed to a new drug may appeal by completing the proforma. Only NHS staff working in Tayside are permitted to appeal against an ADTC classification.

FORMULARY SUB-GROUP

The 4th edition of the Tayside Area Drug Formulary (TADF) was issued in July of this year. The Formulary will become an increasingly important document which is intended to improve prescribing in the Trusts and seamless care between Trusts. Feedback, so far, indicates that it has been well received. Further comments should be sent to Dr Jan Jones at the Health Board (Telephone extension 71132).

The electronic TADF, suitable for use with the “old” GPASS computer system, has been updated and issued to general practitioners on request. A version suitable for “new” GPASS will be available in the near future.

Publication via the NHS and TUHT intranets is currently being explored.

The Formulary Sub-Group will shortly reconvene to undertake the annual revision of TADF. The Tayside dyspepsia guidelines, antibiotic advice and other guidance notes contained within the formulary will likewise be reviewed at this time.

Erratum – p. 39 last para should read “In women who have **not** had a hysterectomy

NOTIFICATION OF NEW DRUGS

Zanamivir (Relenza), a new treatment for influenza virus infection, will be reviewed by the New Drugs Sub-Group as a priority. Meanwhile a fact sheet will be issued by the Drug Information Service during October.

APPEAL AGAINST AREA DRUG AND THERAPEUTICS COMMITTEE

NEW DRUGS CLASSIFICATION

Drug: (include Approved Name, Trade Name, Manufacturer)

Classification assigned by ADTC

Reason for Appeal

.....
.....
.....
.....
.....
.....
.....

Evidence in Support of Appeal

.....
.....
.....
.....
.....
..... continue on reverse of form, if necessary

What Classification Do You Think Should be Assigned to this Drug?

Drug Classifications

- Category 1. Recommendation for general use
- Category 2. On recommendation of specialist
 - 2(a) hospital use only
 - 2(b) shared care
- Category 3. Not recommended – does not offer advantages over existing therapy
- Category 4. Evidence of place in treatment not yet established – to be reviewed

Declaration of Interest

Members of ADTC must make a declaration of interest in respect of new drug products or the manufacturer. You are likewise required to do so.

Do you have a declarable interest in this drug or the pharmaceutical manufacturer? Yes ☐ No ☐

If “Yes”, is this interest: Personal Yes ☐ No ☐

Specific Yes ☐ No ☐

Thank you.

PLEASE COMPLETE AND RETURN THIS FORM TO:

Peter Clough
ADTC Professional Secretary
Drug Information Centre
Department of Pharmacy
Ninewells Hospital and Medical School
Dundee DD1 9SY